Bristol-Myers Squibb Company (BMY)
| Market Cap | 111.25B |
| Revenue (ttm) | 48.03B |
| Net Income (ttm) | 6.04B |
| Shares Out | 2.04B |
| EPS (ttm) | 2.97 |
| PE Ratio | 18.40 |
| Forward PE | 9.27 |
| Dividend | $2.52 (4.61%) |
| Ex-Dividend Date | Jan 2, 2026 |
| Volume | 9,704,319 |
| Open | 54.98 |
| Previous Close | 54.94 |
| Day's Range | 54.23 - 55.18 |
| 52-Week Range | 42.52 - 63.33 |
| Beta | 0.29 |
| Analysts | Buy |
| Price Target | 57.64 (+5.47%) |
| Earnings Date | Feb 5, 2026 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for BMY stock is "Buy." The 12-month stock price target is $57.64, which is an increase of 5.47% from the latest price.
News
Bristol Myers Squibb: The Rerating Was Fast - The Proof Will Be Slow (Rating Downgrade)
Bristol Myers Squibb (BMY) has delivered a ~27% total return in three months, driven by topline growth and dividend strength. With the valuation rebound largely complete, BMY shifts from a high-convic...
Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos Expansion
Bristol-Myers Squibb (BMY) remains a Strong Buy as it accelerates Growth Portfolio revenues and executes strategic oncology expansion. BMY's collaboration with Janux Therapeutics positions it to enter...
Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million
Janux Therapeutics, Inc. (NASDAQ: JANX) on Thursday announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb Co. (NYSE: BMY).
Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug
Janux Therapeutics said on Thursday it has entered a collaboration with Bristol Myers Squibb to develop a new cancer treatment, sending its shares up more than 12% in premarket trading.
Top 10 Dividend Stocks For Uncertain Times
Stocks entered 2026 on a positive note before a global sell-off wiped out gains, driven by tariff tensions, a Greenland tug-of-war, and Japan's bond crisis. In this uncertain environment, dividends ca...
Final Trade: BMY, IGV, SOXX, GEN, AMZN
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
2 Top Blue-Chip Stocks to Buy and Hold in 2026
The undervalued stocks of these reliable large companies look attractive today.
Bristol Myers partners with Microsoft for AI-driven lung cancer detection
Bristol Myers Squibb said on Tuesday it had signed an agreement with Microsoft to use the tech company's AI-enabled radiology platform to help speed up early detection of lung cancer.
Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer.
3 Stock Picks Where Technical Indicators Still Say Buy
Burlington Stores, Ituran Location and Control, and Bristol Myers Squibb have gained since being chosen, and their charts look strong.
Bristol-Myers Squibb Company (BMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Bristol-Myers Squibb Company (BMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--BMS Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos in Adolescents with Symptomatic oHCM.
Bristol Myers Squibb to Present at J.P. Morgan's 44th Annual Healthcare Conference
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Present at J.P. Morgan's 44th Annual Healthcare Conference.
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
This Beaten-Down Pharma Stock Could Make a Turnaround in the New Year
At the current price, investors are paying little for Bristol Myers' pipeline.
Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January
Chevron (CVX) is expected to extend its dividend growth streak to 39 years, but with a muted 3–4% increase amid lower oil prices. CVX's earnings remain under pressure from declining oil prices despite...
Bristol-Myers Squibb: Contrarian Buy For Dividend Hunters, Despite Mounting Growth Headwinds
BMY remains a great Buy, supported by the the deeply discounted valuations, the robust cash flows, the healthier balance sheet, and the secure/richer dividend yields. The Growth Portfolio now drives 5...
Bristol Myers Squibb: A Pharma Giant Trading Like Growth Is Over - It's Not
Bristol Myers Squibb remains significantly undervalued, trading at a forward P/E of 8x, versus the sector median of 19.5x. BMY's growth portfolio now generates 57% of total revenue, growing 18% YoY an...
Jenny Harrington's top dividend plays for 2026
Jenny Harrington, CEO Gilman Hill Asset Management, joins CNBC's "Halftime Report" to share her top dividend plays for 2026.
Bristol-Myers Squibb: Pharma Giant Still Undervalued And Printing Cash Despite Patent Cliff
Bristol-Myers Squibb Company has rebounded solidly, as the market finally recognizes prior pessimism was excessive, driving renewed investor interest. Despite an estimated >60% revenue facing loss of ...
Bristol-Myers Squibb Surges Into Year-End: Why BMY Still Looks Undervalued
Bristol-Myers Squibb remains a "Buy," driven by robust Q3 results and a positive technical setup heading into 2026. BMY raised FY 2025 guidance, with operating EPS targeted at $6.40–$6.60 and net sale...
3 Top Value Stocks to Buy and Hold for 2026
These high-quality stocks with value characteristics look attractive today.
Bristol-Myers Squibb: Still Undervalued And Generating 4.65% Dividend Yield
Bristol-Myers Squibb (BMY) is transitioning from a perceived value trap to a growth-focused, diversified pharmaceutical company. BMY's growth portfolio grew 18% YoY in Q3, offsetting legacy drug decli...